Molekyler

Glucosamine Sulfate

Glucosamine sulfate

A widely used joint-health supplement with a modest observational signal for lower all-cause mortality, though the longevity evidence is not from randomized trials.

Behöver granskas Bevisning: Tier 4
SäkerhetGenerally well tolerated; mild gastrointestinal upset is the most common complaint. Shellfish-derived forms warrant caution in shellfish-allergic individuals; vegetarian/fermented forms exist.
Kategoriamino sugar
Senast verifierad2026-08-16
Juridisk statusDietary supplement in the US; regulated as a food supplement in the EU. Not an FDA-approved drug.
Typisk dos1,500 mg/day glucosamine sulfate, often split into divided doses.
KemiAn amino monosaccharide endogenously synthesized from glucose and the amino acid glutamine; a structural component of glycosaminoglycans and cartilage matrix. Supplied commercially as glucosamine sulfate or glucosamine hydrochloride, often paired with chondroitin.
EvidensObservational cohort data (UK Biobank, NHANES) link glucosamine use to lower all-cause and cardiovascular mortality, but no randomized trial tests mortality outcomes and healthy-user confounding is substantial; joint-pain RCT evidence is formulation-dependent and mixed.
Relaterade produkterGlucosamine-containing joint-health produkter may appear in the database where categorized.

Glucosamine sulfate is one of the most consumed dietary supplements worldwide, taken primarily for osteoarthritis on the rationale that it supplies substrate for cartilage glycosaminoglycan synthesis. The joint-pain evidence is mixed: some trials of the prescription-grade crystalline glucosamine sulfate (Rotta formulation) showed modest symptom benefit, while many larger trials of over-the-counter glucosamine hydrochloride found no meaningful advantage over placebo.

The longevity-relevant signal is observational rather than interventional. Analyses of large UK and US cohorts, including the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), have reported that self-reported glucosamine use is associated with lower all-cause mortality and lower cardiovascular mortality compared with non-use, even after adjustment for standard risk factors. Because users of glucosamine tend to be more health-conscious than non-users, residual confounding by healthy-user behavior is the principal caveat; no randomized trial has tested glucosamine against a placebo for mortality outcomes.

A separate, emerging line of inquiry has examined possible cognitive and neuroprotective effects, including studies probing whether glucosamine use tracks changes in cognitive decline; this evidence is early-stage and not yet sufficient to support a clinical recommendation.

Dosing in studies is typically 1,500 mg/day of glucosamine sulfate, often split. Säkerhet is well established; the most commonly reported effects are mild gastrointestinal upset. Personer with shellfish allergy were historically advised caution because some glucosamine is derived from shellfish chitin, though shellfish-free (fermented or plant-derived) forms are available.

Plain takeaway: glucosamine sulfate has plausible joint-health use with mixed trial evidence, and an intriguing but confounding-prone observational link to lower mortality; it is not a proven longevity drug, and the mortality association should not be read as causal without randomized data.

Vidare läsning

Kurerade externa källor. Externa länkar öppnas i ny flik.